Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kieran F Docherty

Showing results (111-120 of 143) with videos related to

Pageof 15
Sort By:
European Journal of Heart Failure|November 12, 2021
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HFJawad H Butt, Kieran F Docherty, Pardeep S Jhund, et al.
JACC. Heart Failure|December 31, 2021
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection FractionKieran F Docherty, Modele O Ogunniyi, Inder S Anand, et al.
JAMA Cardiology|March 5, 2025
Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HFKirsty McDowell, Kieran F Docherty, Ross T Campbell, et al.
European Journal of Heart Failure|May 15, 2024
Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trialMats Christian Højbjerg Lassen, John W Ostrominski, Silvio E Inzucchi, et al.
Journal of the American College of Cardiology|July 5, 2023
Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart FailureKieran F Docherty, Kirsty McDowell, Paul Welsh, et al.
European Journal of Heart Failure|December 28, 2020
Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HFPooja Dewan, Kieran F Docherty, Olof Bengtsson, et al.
European Journal of Heart Failure|July 17, 2021
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass indexCarly Adamson, Pardeep S Jhund, Kieran F Docherty, et al.
JACC. Heart Failure|February 7, 2021
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HFLi Shen, Søren Lund Kristensen, Olof Bengtsson, et al.
European Journal of Heart Failure|November 7, 2022
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartanMingming Yang, Jawad H Butt, Toru Kondo, et al.
European Heart Journal|November 20, 2024
Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney diseaseJohn W Ostrominski, Mats C Højbjerg Lassen, Brian L Claggett, et al.
Pageof 15

Showing results (111-120 of 143) with videos related to

Sort By:
Pageof 15
European Journal of Heart Failure|November 12, 2021
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HFJawad H Butt, Kieran F Docherty, Pardeep S Jhund, et al.
JACC. Heart Failure|December 31, 2021
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection FractionKieran F Docherty, Modele O Ogunniyi, Inder S Anand, et al.
JAMA Cardiology|March 5, 2025
Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HFKirsty McDowell, Kieran F Docherty, Ross T Campbell, et al.
European Journal of Heart Failure|May 15, 2024
Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trialMats Christian Højbjerg Lassen, John W Ostrominski, Silvio E Inzucchi, et al.
Journal of the American College of Cardiology|July 5, 2023
Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart FailureKieran F Docherty, Kirsty McDowell, Paul Welsh, et al.
European Journal of Heart Failure|December 28, 2020
Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HFPooja Dewan, Kieran F Docherty, Olof Bengtsson, et al.
European Journal of Heart Failure|July 17, 2021
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass indexCarly Adamson, Pardeep S Jhund, Kieran F Docherty, et al.
JACC. Heart Failure|February 7, 2021
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HFLi Shen, Søren Lund Kristensen, Olof Bengtsson, et al.
European Journal of Heart Failure|November 7, 2022
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartanMingming Yang, Jawad H Butt, Toru Kondo, et al.
European Heart Journal|November 20, 2024
Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney diseaseJohn W Ostrominski, Mats C Højbjerg Lassen, Brian L Claggett, et al.
Pageof 15